Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,561 | 1,052 | -19,194 | -3,094 | -3,178 |
| Depreciation Amortization | 546 | 631 | 60 | 38 | 67 |
| Accounts payable and accrued liabilities | 242 | 134 | -85 | -174 | 149 |
| Other Working Capital | 94 | 296 | 100 | -324 | 41 |
| Other Operating Activity | -375 | -8,140 | 15,176 | 223 | -631 |
| Operating Cash Flow | $-6,054 | $-6,028 | $-3,943 | $-3,331 | $-3,553 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -7 | N/A | -4 | -20 | -11 |
| Investing Cash Flow | $-7 | $N/A | $-4 | $-20 | $-11 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 450 | 3,991 | 2,346 | 500 | N/A |
| Debt Issued | 117 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 6,134 | 5,999 | 3,195 | N/A | N/A |
| Other Financing Activity | 0 | -3,986 | 0 | 3,013 | 408 |
| Financing Cash Flow | $6,701 | $6,005 | $5,541 | $3,513 | $408 |
| Beginning Cash Position | 1,835 | 1,858 | 264 | 102 | 3,221 |
| End Cash Position | 2,474 | 1,835 | 1,858 | 264 | 65 |
| Net Cash Flow | $640 | $-23 | $1,594 | $162 | $-3,156 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,054 | -6,028 | -3,943 | -3,331 | -3,553 |
| Capital Expenditure | -7 | N/A | -4 | -20 | -11 |
| Free Cash Flow | -6,061 | -6,028 | -3,947 | -3,351 | -3,564 |